Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors.

Article Details

Citation

Thayer SA, Welcome M, Chhabra A, Fairhurst AS

Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors.

Biochem Pharmacol. 1985 Jan 15;34(2):175-80.

PubMed ID
2981533 [ View in PubMed
]
Abstract

The dihydropyridine (DHP) Ca2+ channel blocking drugs nicardipine, nitrendipine, nimodipine, felodipine, nifedipine and nisoldipine were examined for activity in inhibiting specific (-)-[3H] QNB and [3H]WB4101 binding to the muscarinic and alpha-adrenergic receptors, respectively, of rat brain. Muscarinic receptor binding was affected most by nicardipine, with felodipine having less activity; the other DHP drugs were essentially inactive at 3 X 10(-5) M. The (+)-stereoisomer nicardipine (KI = 4.07 X 10(-7) M) was 27 times more potent than the (-)-isomer in inhibiting [3H]QNB binding, and this inhibition was found to be competitive. This inhibitory effect of nicardipine was not mediated via interaction with the high-affinity DHP binding site assumed to be associated with a Ca2+ channel. (+)-Nicardipine inhibited the binding of [3H]nitrendipine to this DHP binding site of brain, with a K1 of 9.01 X 10(-11) M, and was 10 times more potent than the (-)-isomer. Thus, the muscarinic receptor was 4200 times less sensitive to (+)-nicardipine than was this DHP binding site. Nicardipine was also the most potent DHP drug inhibiting [3H]WB4104 binding to the alpha-adrenergic receptor, although the other drugs were also somewhat active, in the rank order sequence listed above. This effect of nicardipine on the adrenergic receptor was also stereoselective, with (+)-nicardipine (KI = 3.46 X 10(-7) M) being about 3 times more potent than the (-)-isomer, in producing competitive inhibition of radioligand binding. These data suggest that the effects on brain receptors occur as a result of direct, stereospecific effects of DHP drugs on these receptors and are not due to Ca2+ channel blocking activity of these drugs.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
NicardipineAlpha-1A adrenergic receptorProteinHumans
Unknown
Antagonist
Details
NicardipineAlpha-1B adrenergic receptorProteinHumans
Unknown
Antagonist
Details
NicardipineAlpha-1D adrenergic receptorProteinHumans
Unknown
Antagonist
Details
NicardipineMuscarinic acetylcholine receptor M1ProteinHumans
Unknown
Antagonist
Details
NicardipineMuscarinic acetylcholine receptor M2ProteinHumans
Unknown
Antagonist
Details
NicardipineMuscarinic acetylcholine receptor M3ProteinHumans
Unknown
Antagonist
Details
NicardipineMuscarinic acetylcholine receptor M4ProteinHumans
Unknown
Antagonist
Details
NicardipineMuscarinic acetylcholine receptor M5ProteinHumans
Unknown
Antagonist
Details